Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O14531

UPID:
DPYL4_HUMAN

ALTERNATIVE NAMES:
Collapsin response mediator protein 3; UNC33-like phosphoprotein 4

ALTERNATIVE UPACC:
O14531; B2RMQ1; D3DRG5; O00240; Q5T0Q7

BACKGROUND:
The protein known as Dihydropyrimidinase-related protein 4, with alternative names Collapsin response mediator protein 3 and UNC33-like phosphoprotein 4, is integral to neuronal development. It supports class 3 semaphorins signaling, which is vital for cytoskeleton remodeling, axon guidance, and neuronal growth cone collapse, underscoring its importance in cell migration and neural circuit formation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Dihydropyrimidinase-related protein 4 offers a promising avenue for developing novel therapeutic approaches. Given its critical role in neural development and plasticity, targeting this protein could lead to breakthroughs in treating neurological conditions and promoting recovery from neural injuries.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.